
Dexcom (DXCM) · Medical Devices
Dexcom Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Slides (10 pages)Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Dexcom's CONNECT trial showed CGM benefits for type 2 diabetes patients not on insulin, while a Stelo app relaunch and Nutrisense acquisition push it toward broader, consumer-facing glucose sensing.
Dexcom's main product news this quarter was clinical and consumer. The CONNECT randomized controlled trial found that CGM use in people with type 2 diabetes not using insulin improved glucose control compared with routine care. Dexcom also began launching a reimagined Stelo app with AI-driven insights and better food logging, and completed the acquisition of Nutrisense. International revenue grew 19% reported, outpacing the U.S.
Management is steering toward a much larger user base, citing about 9 million people in the U.S. who have CGM coverage but don't use it, and a long-term outlook through 2030 presented at Investor Day. The plan depends on converting nearly 50% of the U.S. base to G7 15 Day by year end, extending coverage, and a CMS decision expected this year. The tension is that growth rests on payer and regulatory decisions outside Dexcom's control.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Slides & documents
Open the slide deck (PDF, 10 pages) ↗
Showing the first 6 of 10 pages.
From Dexcom investor relations
SEC filing
Key numbers
- Revenue · GAAP
- $1.308 billion
- Net income · GAAP
- $249.1 million
- Diluted EPS · GAAP
- $0.64
- Non-GAAP diluted EPS · non-GAAP
- $0.70
- Gross margin · GAAP
- 63.4%
- Operating income · GAAP
- $318.3 million
- Operating margin · GAAP
- 24.3%
up 13% from a year ago on a reported basis
up from $179.8 million a year ago
up from $0.45 a year ago
up from $0.48 a year ago
up from 59.5% a year ago
up from $212.6 million a year ago
up 590 basis points from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| U.S. revenue | $933.4M | up 11% from a year ago |
| International revenue | $375.0M | up 19% reported, 16% organic |
Where each number comes from
- Revenue: “Revenue grew 13% year-over-year to $1.308 billion on a reported basis and 12% year-over-year on an organic1 basis.”
- Net income: “GAAP net income was $249.1 million, or $0.64 per diluted share, for the second quarter of 2026, compared to GAAP net income of $179.8 million”
- Diluted EPS: “GAAP net income was $249.1 million, or $0.64 per diluted share, for the second quarter of 2026, compared to GAAP net income of $179.8 million”
- Non-GAAP diluted EPS: “Non-GAAP net income* was $269.1 million, or $0.70 per diluted share, for the second quarter of 2026”
- Gross margin: “GAAP gross profit totaled $830.0 million or 63.4% of revenue for the second quarter of 2026, compared to $688.8 million or 59.5% of revenue”
- Operating income: “GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025.”
- Operating margin: “GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025.”
- U.S. revenue: “Total revenue | $933.4 | $375.0 | $1,308.4 | $841.0 | $316.1 | $1,157.1 Six Months Ended June 30, 2026”
- International revenue: “Total revenue | $933.4 | $375.0 | $1,308.4 | $841.0 | $316.1 | $1,157.1 Six Months Ended June 30, 2026”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.3B | +13.1% | +9.8% |
| Operating income | $318.3M | +49.7% | +24.7% |
| Net income | $249.1M | +38.5% | +24.9% |
| Diluted EPS | $0.64 | +42.2% | +25.5% |
| Free cash flow | $184.5M | −11.7% | −58.9% |
| Gross margin | 63.4% | +3.9 pts | +0.5 pts |
| Operating margin | 24.3% | +5.9 pts | +2.9 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue | fiscal year 2026 | $5.18 - $5.25 billion |
| Non-GAAP gross profit margin | fiscal year 2026 | approximately 64% |
| Non-GAAP operating margin | fiscal year 2026 | approximately 23.5-24% |
| Adjusted EBITDA margin | fiscal year 2026 | approximately 31.5-32% |
Key takeaways
CONNECT trial supports CGM for non-insulin type 2
Dexcom reported that CGM use among people with type 2 diabetes not using insulin produced clinically meaningful, statistically significant improvements in glucose control versus routine care. This evidence underpins the push into a much larger patient group.
Stelo app relaunched with AI insights
Dexcom started rolling out a reimagined Stelo experience with a more consumer-friendly feel, AI-driven insights and enhanced food logging. It signals deeper investment in the over-the-counter consumer segment.
Nutrisense acquisition completed in the quarter
Dexcom completed its acquisition of Nutrisense during the second quarter, adding to its consumer and wellness-oriented glucose offerings. Acquired non-CGM revenue was only $0.2 million, so it is early.
G7 15 Day conversion and international clearance
Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end, and Health Canada was the first international regulator to clear it. The product also contributes to expected gross margin gains.
Payer coverage broadens, CMS decision pending
Dexcom now has coverage for all people with diabetes across the 4 largest commercial PBMs, and expects to hear back from CMS before the end of this year. Coverage decisions are the main gate to the roughly 9 million covered but non-using people in the U.S.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $1.1B * |
| Q1 2025 | $1.0B |
| Q2 2025 | $1.2B |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.3B * |
| Q1 2026 | $1.2B |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.3B |
Data
| Q1 2025 | $0.27 |
| Q2 2025 | $0.45 |
| Q3 2025 | $0.70 |
| Q1 2026 | $0.51 |
| Q2 2026 | $0.64 |
| Q3 2026 | $0.72 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 17.0% |
| Q1 2025 | 12.9% |
| Q2 2025 | 18.4% |
| Q3 2025 | 20.1% |
| Q4 2025 | 25.6% |
| Q1 2026 | 21.4% |
| Q2 2026 | 24.3% |
| Q3 2026 | 24.3% |
Data
| Q4 2024 | $176.8M |
| Q1 2025 | $96.8M |
| Q2 2025 | $208.9M |
| Q3 2025 | $579.4M |
| Q4 2025 | $192.1M |
| Q1 2026 | $449.0M |
| Q2 2026 | $184.5M |
| Q3 2026 | $272.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What did Dexcom's CONNECT trial show?
It showed that CGM use among people with type 2 diabetes not using insulin led to clinically meaningful and statistically significant improvements in glucose control compared with routine care. Dexcom says it reinforces confidence in its long-range plan.
What is new with Dexcom's Stelo?
Dexcom began launching a fully reimagined Stelo app with a more consumer-friendly feel, new AI-driven insights and enhanced food logging. It also completed the Nutrisense acquisition during the quarter.
How far along is the G7 15 Day rollout?
Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end. Health Canada became the first international regulator to clear it.
How large is the untapped U.S. opportunity Dexcom cites?
Approximately 9 million people in the U.S. have coverage for CGM but are not yet using it. Coverage now spans all people with diabetes across the 4 largest commercial PBMs.
What did Dexcom lay out at Investor Day?
Dexcom hosted its 2026 Investor Day at its Arizona manufacturing facility, highlighting its market opportunity, strategy and innovation efforts. It introduced a new long-term financial outlook through 2030.





